Showing results (51-60 of 92) with videos related to
Sort By:
Pageof 10
Revista De Psiquiatria Y Salud Mental|August 30, 2021
The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study designMiguel Bernardo, Silvia Amoretti, Manuel Jesús Cuesta, et al.Journal of Psychiatric Research|May 28, 2023
Long-term outcomes of deep brain stimulation for treatment-resistant schizophrenia: Exploring potential targetsJuan Ángel Aibar-Durán, Iluminada Corripio Collado, Alexandra Roldán Bejarano, et al.The Journal of Clinical Psychiatry|September 19, 2017
Persistent Negative Symptoms in First-Episode Psychosis: Early Cognitive and Social Functioning Correlates and Differences Between Early and Adult OnsetOlga Puig, Immaculada Baeza, Elena de la Serna, et al.The Journal of Clinical Psychiatry|September 16, 2021
Premorbid Characteristics as Predictors of Early Onset Versus Adult Onset in Patients With a First Episode of PsychosisInmaculada Baeza, Elena de la Serna, Silvia Amoretti, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 4, 2021
The functioning assessment short test (FAST) applied to first-episode psychosis: Psychometric properties and severity thresholdsSilvia Amoretti, Gisela Mezquida, Adriane R Rosa, et al.Journal of Psychiatric Research|June 3, 2020
Brain metabolic changes in patients with treatment resistant schizophrenia treated with deep brain stimulation: A series of casesAlexandra Roldán, Maria J Portella, Frederic Sampedro, et al.Schizophrenia Research|August 8, 2021
Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosisLeticia González-Blanco, María Paz García-Portilla, Miguel Gutiérrez, et al.Frontiers in Endocrinology|December 22, 2022
The effect of early life events on glucose levels in first-episode psychosisClemente Garcia-Rizo, Bibiana Cabrera, Miquel Bioque, et al.JMIR Human Factors|May 15, 2025
Mobile Therapeutic Attention for Treatment-Resistant Schizophrenia (m-RESIST) Solution for Improving Clinical and Functional Outcomes in Treatment-Resistant Schizophrenia: Prospective, Multicenter Efficacy StudyJussi Seppälä, Eva Grasa, Anna Alonso-Solis, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 9, 2017
Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patientsSergi Mas, Patricia Gassó, Mercé Torra, et al.Pageof 10